Sarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $182.00 by Analysts at Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective hoisted by Royal Bank of Canada from $142.00 to $182.00 in a report issued on Friday, Benzinga reports. They currently have a sector perform rating on the biotechnology company’s stock.

Several other analysts have also recently weighed in on SRPT. BMO Capital Markets reissued an outperform rating and set a $170.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 14th. Citigroup boosted their price objective on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a buy rating in a report on Thursday, February 29th. Piper Sandler began coverage on Sarepta Therapeutics in a report on Friday, May 31st. They set an overweight rating and a $157.00 price objective for the company. Robert W. Baird boosted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an outperform rating in a report on Friday. Finally, TheStreet raised Sarepta Therapeutics from a d rating to a c- rating in a report on Monday, March 4th. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $177.65.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $160.72 on Friday. The stock has a 50-day simple moving average of $125.56 and a 200 day simple moving average of $119.73. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25. The stock has a market capitalization of $15.19 billion, a price-to-earnings ratio of 1,461.09 and a beta of 0.96.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. During the same period in the previous year, the business posted ($1.44) earnings per share. The firm’s revenue for the quarter was up 63.1% compared to the same quarter last year. On average, research analysts anticipate that Sarepta Therapeutics will post 2.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now owns 18,125 shares in the company, valued at approximately $2,537,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors have recently bought and sold shares of SRPT. Principal Securities Inc. bought a new stake in Sarepta Therapeutics in the 4th quarter valued at approximately $26,000. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. raised its stake in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares in the last quarter. Cary Street Partners Investment Advisory LLC raised its stake in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares in the last quarter. Finally, New Covenant Trust Company N.A. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $32,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.